Our initial focus is on developing novel immuno-oncology (IO) therapeutics targeting butyrophilins/butyrophilin-like proteins [BTN(L)s] to treat a range of solid tumors and hematologic cancers. Initially, our programs were centered around the powerful mechanism of action of γ9δ2 T cells, however, as our understanding of the BTN(L) biology has evolved we have utilized this knowledge to generate intellectual property around targeting other immune cell populations to create a diversified and deep pipeline.
Differentiated and Diversified Pipeline with First-in-class Potential
Abbreviations: AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; DLBCL, diffuse large B-cell lymphomas; IL2, interleukin-2; LAG3i, Lymphocyte-Activation Gene-3 inhibitor; MCL, Mantle cell lymphoma; MDS, Myelodysplastic syndromes; MM, Multiple myeloma; PDL1i, programmed cell death protein 1 inhibitor.